- Home
- ILMN vs LII Comparison
ILMN vs LII Comparison
Compare ILMN & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- LII
- Stock Information
- Founded
- ILMN 1998
- LII 1895
- Country
- ILMN United States
- LII United States
- Employees
- ILMN N/A
- LII N/A
- Industry
- ILMN Medical Specialities
- LII Industrial Machinery/Components
- Sector
- ILMN Health Care
- LII Industrials
- Exchange
- ILMN Nasdaq
- LII Nasdaq
- Market Cap
- ILMN 13.1B
- LII 20.6B
- IPO Year
- ILMN 2000
- LII 1999
- Fundamental
- Price
- ILMN $97.15
- LII $604.04
- Analyst Decision
- ILMN Buy
- LII Hold
- Analyst Count
- ILMN 17
- LII 11
- Target Price
- ILMN $124.35
- LII $606.30
- AVG Volume (30 Days)
- ILMN 2.4M
- LII 345.9K
- Earning Date
- ILMN 07-31-2025
- LII 07-23-2025
- Dividend Yield
- ILMN N/A
- LII 0.86%
- EPS Growth
- ILMN N/A
- LII 30.10
- EPS
- ILMN N/A
- LII 22.45
- Revenue
- ILMN $4,337,000,000.00
- LII $5,366,800,000.00
- Revenue This Year
- ILMN N/A
- LII $3.46
- Revenue Next Year
- ILMN $3.15
- LII $5.61
- P/E Ratio
- ILMN N/A
- LII $26.91
- Revenue Growth
- ILMN N/A
- LII 7.78
- 52 Week Low
- ILMN $68.70
- LII $500.10
- 52 Week High
- ILMN $156.66
- LII $682.50
- Technical
- Relative Strength Index (RSI)
- ILMN 59.14
- LII 60.69
- Support Level
- ILMN $95.09
- LII $588.69
- Resistance Level
- ILMN $101.28
- LII $624.10
- Average True Range (ATR)
- ILMN 3.31
- LII 12.98
- MACD
- ILMN -0.27
- LII 3.33
- Stochastic Oscillator
- ILMN 58.10
- LII 70.86
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About LII Lennox International Inc.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.